Roberto Freilone

Turin, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 39 publications

T-cell acute lymphoblastic leukemia in adults: current treatment approaches and future perspectives.

T-cell acute lymphoblastic leukemia in adults: current treatment approaches and future perspectives.

Journal: Expert review of hematology

Published: May 21, 2026

Infections and CAR-T cells for the treatment of lymphoid malignancies: a narrative review.

Infections and CAR-T cells for the treatment of lymphoid malignancies: a narrative review.

Journal: Frontiers in medicine

Published: March 13, 2026

Case of brexu-cel at first relapse in an elderly patient

Case of brexu-cel at first relapse in an elderly patient

Journal: Recenti progressi in medicina

Published: January 22, 2026

Systemic Inflammation and CAR-T Specific Toxicities as Major Drivers of Nonrelapse Mortality: Analysis from the Italian Prospective Observational CART-SIE Study.

Systemic Inflammation and CAR-T Specific Toxicities as Major Drivers of Nonrelapse Mortality: Analysis from the Italian Prospective Observational CART-SIE Study.

Journal: Transplantation and cellular therapy

Published: October 19, 2025

Mechanisms of Resistance to CAR T-Cells and How to Overcome Them.

Mechanisms of Resistance to CAR T-Cells and How to Overcome Them.

Journal: Methods and protocols

Published: July 27, 2025

Rituximab, bendamustine, and cytarabine followed by venetoclax in older patients with high-risk mantle cell lymphoma (FIL_V-RBAC): a multicentre, single-arm, phase 2 study.

Rituximab, bendamustine, and cytarabine followed by venetoclax in older patients with high-risk mantle cell lymphoma (FIL_V-RBAC): a multicentre, single-arm, phase 2 study.

Journal: The Lancet. Haematology

Published: April 28, 2025

Overcoming barriers to referral for CAR T-cell therapy in patients with non-Hodgkin aggressive B-cell lymphomas: A Delphi consensus.

Overcoming barriers to referral for CAR T-cell therapy in patients with non-Hodgkin aggressive B-cell lymphomas: A Delphi consensus.

Journal: Cytotherapy

Published: April 22, 2025

Efficacy and toxicity of brexucabtagene autoleucel in the treatment of high-risk mantle cell lymphoma: description of a clinical case

Efficacy and toxicity of brexucabtagene autoleucel in the treatment of high-risk mantle cell lymphoma: description of a clinical case

Journal: Recenti progressi in medicina

Published: March 14, 2025

Chronic myeloid leukemia outcomes according to baseline risk and first-line treatment in real-world settings: Data from the Italian Network/CML Campus.

Chronic myeloid leukemia outcomes according to baseline risk and first-line treatment in real-world settings: Data from the Italian Network/CML Campus.

Journal: Cancer

Published: February 23, 2025

Arsenic trioxide neurotoxicity in acute promyelocytic leukemia patients: a single center experience.

Arsenic trioxide neurotoxicity in acute promyelocytic leukemia patients: a single center experience.

Journal: Leukemia & lymphoma

Published: November 08, 2024

Bispecific Antibodies for Lymphoid Malignancy Treatment.

Bispecific Antibodies for Lymphoid Malignancy Treatment.

Journal: Cancers

Published: October 14, 2024

Safety run-in and part 1 of GIMEMA AML1718: venetoclax combined with FLAI as induction treatment in non-low-risk AML.

Safety run-in and part 1 of GIMEMA AML1718: venetoclax combined with FLAI as induction treatment in non-low-risk AML.

Journal: Blood advances

Published: September 23, 2024

Showing 1-12 of 39

Last Updated: 09/26/2026